Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer

被引：10
作者：
Schipilliti, Francesca Matilde [1 ]
Drittone, Denise [1 ]
Mazzuca, Federica [2 ]
La Forgia, Daniele [3 ]
Guven, Deniz Can [4 ]
Rizzo, Alessandro [3 ]
机构：
[1] Univ Sapienza Rome, St Andrea Hosp, Oncol Dept, Rome, Italy
[2] Sapienza Univ, Dept Clin & Mol Med, Oncol Unit, Azienda Osped Univ St Andrea, Rome, Italy
[3] IRCCS Ist Tumori Giovanni Paolo II, Bari, Italy
[4] Hacettepe Univ, Dept Med Oncol, Canc Inst, TR-06100 Ankara, Turkiye
来源：
HELIYON | 2024年 / 10卷 / 07期
关键词：
Breast cancer; Triple -negative breast cancer; ADC; Antibody -drug conjugates; Dato-DXd; Datopotamab deruxtecan; TRASTUZUMAB EMTANSINE; SACITUZUMAB GOVITECAN; PHASE I/II; OPEN-LABEL; SURVIVAL; EFFICACY; TROP-2;
D O I：
10.1016/j.heliyon.2024.e28385
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Triple negative breast cancer (TNBC) represents the breast cancer subtype with least favorable outcome because of the lack of effective treatment options and its molecular features. Recently, ADCs have dramatically changed the breast cancer treatment landscape; the anti-TROP2 ADC Sacituzumab Govitecan has been approved for treatment of previously treated, metastatic TNBC patients. The novel ADC Datopotecan-deruxtecan (Dato-DXd) has recently shown encouraging results for TNBC. In the current paper, we summarize and discuss available data regarding this TROP-2 directed agent mechanism of action and pharmacologic activity, we describe first results on efficacy and safety of the drug and report characteristics, inclusion criteria and endpoints of the main ongoing clinical trials.
引用
收藏
页数：7
相关论文
共 50 条
  • [41] An Erlotinib gold(I) conjugate for combating triple-negative breast cancer
    Ortega, Enrique
    Zamora, Ana
    Basu, Uttara
    Lippmann, Petra
    Rodriguez, Venancio
    Janiak, Christoph
    Ott, Ingo
    Ruiz, Jose
    JOURNAL OF INORGANIC BIOCHEMISTRY, 2020, 203
  • [42] Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape
    Adams, E.
    Wildiers, H.
    Neven, P.
    Punie, K.
    ESMO OPEN, 2021, 6 (04)
  • [43] Triple-negative breast cancer
    Chacon, Reinaldo D.
    Costanzo, Maria V.
    BREAST CANCER RESEARCH, 2010, 12
  • [44] Triple-negative breast cancer
    Stockmans, Gert
    Deraedt, Karen
    Wildiers, Hans
    Moerman, Philippe
    Paridaens, Robert
    CURRENT OPINION IN ONCOLOGY, 2008, 20 (06) : 614 - 620
  • [45] Novel Treatment Approaches for Triple-Negative Breast Cancer
    Telli, Melinda L.
    Ford, James M.
    CLINICAL BREAST CANCER, 2010, 10 : E16 - E22
  • [46] Emerging Novel Therapeutics in Triple-Negative Breast Cancer
    Lyons, Tomas G.
    Traina, Tiffany A.
    BREAST CANCER METASTASIS AND DRUG RESISTANCE: CHALLENGES AND PROGRESS, 2ND EDITION, 2019, 1152 : 377 - 399
  • [47] Excellent effects and possible mechanisms of action of a new antibody–drug conjugate against EGFR-positive triple-negative breast cancer
    Dan-Dan Zhou
    Wei-Qi Bai
    Xiao-Tian Zhai
    Li-Ping Sun
    Yong-Su Zhen
    Zhuo-Rong Li
    Qing-Fang Miao
    Military Medical Research, 8
  • [48] Recent progress in antibody-based therapeutics for triple-negative breast cancer
    Ning, Wen-Jing
    Liu, Xue
    Zeng, Hong-Ye
    An, Zhi-Qiang
    Luo, Wen-Xin
    Xia, Ning-Shao
    EXPERT OPINION ON DRUG DELIVERY, 2022, 19 (07) : 815 - 832
  • [49] Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth
    Cheung, Anthony
    Chenoweth, Alicia M.
    Johansson, Annelie
    Laddach, Roman
    Guppy, Naomi
    Trendell, Jennifer
    Esapa, Benjamina
    Mavousian, Antranik
    Navarro-Llinas, Blanca
    Haider, Syed
    Romero-Clavijo, Pablo
    Hoffmann, Ricarda M.
    Andriollo, Paolo
    Rahman, Khondaker M.
    Jackson, Paul
    Tsoka, Sophia
    Irshad, Sheeba
    Roxanis, Ioannis
    Grigoriadis, Anita
    Thurston, David E.
    Lord, Christopher J.
    Tutt, Andrew N. J.
    Karagiannis, Sophia N.
    CLINICAL CANCER RESEARCH, 2024, 30 (15) : 3298 - 3315
  • [50] Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma
    McNamara, Blair
    Greenman, Michelle
    Bellone, Stefania
    Santin, Luca A.
    Demirkiran, Cem
    Mutlu, Levent
    Hartwich, Tobias Max Philipp
    Yang-Hartwich, Yang
    Ratner, Elena
    Schwartz, Peter E.
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY, 2024, 189 : 16 - 23
12345